Morning Buzz: salesforce.com (CRM), Square (SQ), Yahoo (YHOO), KaloBios (KBIO)

Wall Street

salesforce.com, inc. (CRM) reported third-quarter EPS of $0.21 compared to the consensus estimate of $0.19. Revenues increased 23.7% from last year to $1.71 billion. Analysts expected revenues of $1.70 billion. For the current quarter, the pioneer in software-as-a-service provided EPS guidance of $0.18 to $0.19 versus consensus of $0.19 per share. The company also issued revenue projection of $1.78 to $1.79 billion, compared to the consensus revenue estimate of $1.78 billion.

Salesforce.com stock was up more than 5% to $81.50 in pre-market hours, following the release of its results.

Square (SQ) – Shares of the San Francisco-based company will begin trading today on the NYSE at $9 a share, well below the expected range of $11 to $13, and also below the $15.46/shr the electronic payments company had set for private investors during its fundraising round last year. That puts Square’s valuation, a company that has lost more than $300 million between the fiscal 2012 and 2014, at around $2.9 billion.

Shares Yahoo! Inc. (YHOO) were up slightly this morning following a WSJ report that said the web portal is being pressured by activist investor Starboard Value to drop its planned spinoff of its Alibaba (BABA) stake. Starboard, which said it is a “significant shareholder” in Yahoo, believes the spinoff comes with the risk of a hefty tax bill. The Journal reports Yahoo is being urged instead to sell its struggling Internet business.

Shares of KaloBios Pharmaceuticals, Inc. (KBIO) rocketed over 687 percent to $16.30 in pre-market hours following news that former Retrophin CEO and current Turing Pharma CEO Martin Shkreli bought 1.2 million shares, or more than 50% of KaloBios stock.

Shares were bought Monday-Tuesday at prices ranging from $0.30 to 2.45 per share.

KBIOS topped $19 in extended trading Wednesday in New York.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


*

This site uses Akismet to reduce spam. Learn how your comment data is processed.